"China Sorafenib Market, 2010-2019" Published

From: Fast Market Research, Inc.
Published: Tue Aug 04 2015

The incidence of liver cancer and kidney cancer in China grows gradually. According to the Guidelines for Kidney Cancer Diagnosis and Treatment in China (the 2013 version), kidney cancer accounts for 2%-3% of adult malignant tumors in China and reports an obvious rise in incidence in recent years in China. Kidney cancer has surpassed bladder cancer to become the first in death related with urological tumors with its incidence growing at an average rate of 6.5% during the past two decades. According to the World Cancer Report 2014, China ranked first in the new cases of liver cancer and its death toll. Currently, liver cancer, with 0.257 in 1 million suffering from it, has become the third malignant tumor after stomach cancer and lung cancer in terms of mortality. As a novel small molecular multi-targeted inhibitor of tyrosine kinase, sorafenib is approved by FDA to treat unresectable advanced renal cell carcinoma and unresectable or metastasized primary hepatocellular carcinoma. Co-developed by Bayer and Onyx Pharmaceuticals, sorafenib got imported drug license in 2006 and was approved by China Food and Drug Administration to enter the market for the treatment of liver cancer in 2008.

Full Report Details at
- http://www.fastmr.com/prod/1024237_china_sorafenib_20102019.aspx?afid=301

According to CRI's survey on 20 sample hospitals in key regions in China, sales value of sorafenib was CNY 147 million in 2013 and CNY 165 million in 2014, increasing 12.24% year on year.

With the degradation of environmental pollution and changes in lifestyle, the incidence of liver cancer keeps rising. Hence the vast demand for sorafenib in China. Currently, sorafenib in the Chinese market all come from Bayer AG i.e. Bayer enjoys a market share of 100%.

Readers can get at least the following information from this report:

* market size of sorafenib in China
* major manufacturers of sorafenib in Chinese market
* retail price of sorafenib in China
* market outlook of sorafenib in China

The author suggests the following groups of people purchase this report:

* manufacturers of anti-tumor drugs
* investors/ research institutions interested in Chinese medicine market
* any interest in the medicine market, please contact CRI for customized survey service

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Onyx Pharmaceuticals, Inc. (ONXX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Onyx Pharmaceuticals, Inc. (ONXX) - Strategic SWOT Analysis Review
- Peritoneal Cancer - Pipeline Review, H1 2015
- Frontier Pharma: Liver Cancer - Identifying and Commercializing First-in-Class Innovation
- Lung Adenocarcinoma - Pipeline Review, H2 2014

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »